review Open AccessTop 1% cited
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
Hepatology · 2017 · Vol. 65(5) · pp. 1557–1565
Parambir S. Dulai(University of California, San Diego)Siddharth Singh(University of California, San Diego)Janki Patel(University of California, San Diego)Meera Soni(University of California, San Diego)Larry J. Prokop(Mayo Clinic in Arizona)Zobair M. Younossi(Inova Fairfax Hospital)Giada Sebastiani(McGill University Health Centre)Mattias Ekstedt(Linköping University)Hannes Hagström(Karolinska Institutet)Patrik Nasr(Linköping University)Per Stål(Karolinska University Hospital)Vincent Wai‐Sun Wong(Chinese University of Hong Kong)Stergios Kechagias(Linköping University)Rolf Hultcrantz(Karolinska Institutet)Rohit Loomba✉(University of California, San Diego)
Abstract
The risk of liver-related mortality increases exponentially with increase in fibrosis stage; these data have important implications in assessing the utility of each stage and benefits of regression of fibrosis from one stage to another. (Hepatology 2017;65:1557-1565).
Liver Disease Diagnosis and TreatmentLiver Disease and TransplantationLiver Diseases and ImmunityNonalcoholic fatty liver diseaseInternal medicineMedicineFibrosisStage (stratigraphy)GastroenterologyConfidence intervalMeta-analysisPopulationHazard ratio
MeSH terms
FibrosisHumansLiverNon-alcoholic Fatty Liver Disease
Funding
- Bristol-Myers Squibb
- Gilead Sciences
- American Gastroenterological Association
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Environmental Health Sciences
Citations
1,846
FWCI
97.16
field-weighted impact
References
23
Percentile
100%
vs. same field & year
Citations per year
Cited by
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Hepatology · 2023 · 2,046 citations
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
Journal of Hepatology · 2021 · 1,641 citations
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
Journal of Hepatology · 2018 · 1,972 citations
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
Gastroenterology · 2019 · 1,418 citations
Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease
Cell Metabolism · 2017 · 1,075 citations
Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH
Transplantation · 2018 · 444 citations
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
Journal of Hepatology · 2017 · 1,051 citations
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
Journal of Hepatology · 2019 · 2,150 citations
References
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Hepatology · 2012 · 3,804 citations
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Gastroenterology · 2015 · 2,900 citations
Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆
Gastroenterology · 1999 · 3,359 citations
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Gastroenterology · 2005 · 2,883 citations
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Annals of Internal Medicine · 2009 · 37,606 citations
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
Hepatology · 2014 · 2,228 citations
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
BMJ · 2009 · 82,871 citations
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
Hepatology · 2015 · 10,578 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.